Ligand Pharmaceuticals Inc (LGND)
Stock-Based Compensation
$13.65M
Quarterly · Period ending: · USD
LGND Stock-Based Compensation
Latest reported$13.65Mperiod ending
Latest reported$13.65Mperiod ending
LGND Quarterly Stock-Based Comp ($0.00 → $13.65M)
Quarterly stock-based compensation
High-resolution chart · PNG
LGND stock-based compensation history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 13,653,000 | |
| 10,596,000 | |
| 14,270,000 | |
| 14,746,000 | |
| 0 | |
| 0 | |
| 7,524,000 | |
| 26,231,000 | |
| 11,060,000 | |
| 7,334,000 | |
| 0 | |
| 6,884,000 | |
| 7,207,000 | |
| 0 | |
| 0 | |
| 12,597,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 8,405,000 | |
| 9,975,000 | |
| 7,740,000 | |
| 7,359,000 | |
| 5,653,000 | |
| 6,300,000 | |
| 6,297,000 | |
| 6,571,000 | |
| 5,347,000 | |
| 6,009,000 | |
| 5,470,000 | |
| 4,812,000 | |
| 4,555,000 | |
| 8,998,000 | |
| 5,248,000 | |
| 4,624,000 | |
| 6,045,000 | |
| 5,203,000 | |
| 4,924,000 | |
| 4,648,000 | |
| 4,118,000 | |
| 2,947,000 | |
| 2,836,000 | |
| 3,761,000 | |
| 2,914,000 | |
| 2,475,000 | |
| 3,702,000 | |
| 3,026,000 | |
| 2,067,000 | |
| 1,517,000 | |
| 1,533,000 | |
| 1,492,000 | |
| 1,124,000 | |
| 951,000 | |
| 1,013,000 | |
| 1,394,000 | |
| 709,000 | |
| 705,000 | |
| 950,000 | |
| 1,244,000 | |
| 452,000 | |
| 311,000 | |
| 557,000 | |
| 833,000 | |
| 624,000 | |
| 924,000 | |
| 741,000 | |
| 880,000 | |
| 820,000 | |
| 3,607,000 | |
| 0 | |
| 0 | |
| 996,000 | |
| 7,580,000 | |
| 0 | |
| 0 | |
| 5,554,000 | |
| 5,338,000 | |
| 0 | |
| 0 | |
| 814,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |